5 completed, 2 terminated, 1 active not recruiting, 1 recruiting. 10 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Completed 5, Terminated 2, Active not recruiting 1, Recruiting 1, Withdrawn 1 |
| Phase 2 | 7 | Completed 4, Terminated 2, Active not recruiting 1 |
Follow Sudden Infant Death: new trials by email Literature Review of Sudden Infant Death trials Research Report on Sudden Infant Death
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of HMI-203 in ERT-Treated Adults With MPS II Genetic HMI-203 - Mucopolysaccharidosis II | Phase 1 | Withdrawn | Homology Medicines, Inc | 2022-09-08 | 2023-08-28 | |
| PEARL (PrEnAtal Enzyme Replacement Therapy for Lysosomal Storage Disorders) Aldurazyme (laronidase) - MPS I, MPS II | Phase 1 | Recruiting | University of California, San Francisco | 10 | 2021-07-01 | 2026-03-17 |
| RGX-121 Gene Therapy in Children 5 Years of Age and Over With MPS II (Hunter Syndrome) RGX-121 - Mucopolysaccharidosis Type II (MPS II) | Phase 1 / Phase 2 | Completed | REGENXBIO Inc. | 6 | 2021-03-11 | 2025-01-28 |
| A Study of Tividenofusp Alfa (DNL310) in Pediatric Participants With Hunter Syndrome tividenofusp alfa - Mucopolysaccharidosis II | Phase 1 / Phase 2 | Active not recruiting | Denali Therapeutics Inc. | 47 | 2020-07-16 | 2025-08-07 |
| Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II SB-913 - Mucopolysaccharidosis II, MPS II | Phase 1 / Phase 2 | Terminated | Sangamo Therapeutics | 9 | 2017-05-11 | 2022-10-25 |
| Safety and Dose Ranging Study of Insulin Receptor MoAb-IDS Fusion Protein in Patients With Hunter Syndrome AGT-182 - Mucopolysaccharidosis II | Phase 1 | Completed | ArmaGen, Inc | 6 | 2015-04-01 | 2018-09-18 |
| Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders hematopoietic stem cell infusion - Hurler Syndrome (MPS I), Hurler-Scheie Syndrome | Phase 1 / Phase 2 | Terminated | Talaris Therapeutics Inc. | 3 | 2011-04-01 | 2023-04-12 |
| An Extension Study of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase-IT in Conjunction With Elaprase in Pediatric Participants With Hunter Syndrome and Cognitive Impairment Idursulfase-IT, Elaprase - Hunter Syndrome | Phase 1 / Phase 2 | Completed | Takeda | 15 | 2010-08-01 | 2025-08-06 |
| To Evaluate the Safety and Efficacy of GC1111 (Recombinant Human Iduronate-2-sulfatase) in Hunter Syndrome Patients GC1111_0.5mg/kg, GC1111_1.0mg/kg, Elaprase_0.5mg/kg - Mucopolysaccharidosis II | Phase 1 / Phase 2 | Completed | Green Cross Corporation | 31 | 2010-05-01 | 2012-02-14 |
| A Safety and Dose Ranging Study of Idursulfase (Intrathecal) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Hunter Syndrome Who Have Central Nervous System Involvement and Are Receiving Treatment With Elaprase® Control, Idursulfase IT (1 mg), Idursulfase IT (10 mg) - Hunter Syndrome | Phase 1 / Phase 2 | Completed | Shire | 16 | 2009-11-18 | 2021-06-28 |
Mucopolysaccharidosis II (9) · Lysosomal Storage Diseases (2) · Adrenoleukodystrophy (1) · Gaucher Disease (1) · Leukodystrophy, Globoid Cell (1) · Leukodystrophy, Metachromatic (1) · Mucopolysaccharidoses (1) · Mucopolysaccharidosis I (1) · Mucopolysaccharidosis III (1) · Mucopolysaccharidosis IV (1) · Mucopolysaccharidosis VI (1) · Mucopolysaccharidosis VII (1) · Niemann-Pick Diseases (1) · Sandhoff Disease (1)
Carbohydrate Metabolism, Inborn Errors (10) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (10) · Connective Tissue Diseases (10) · Death (10) · Death, Sudden (10) · Genetic Diseases, Inborn (10) · Infant Death (10) · Metabolic Diseases (10) · Metabolism, Inborn Errors (10) · Mucinoses (10) · Nervous System Diseases (10) · Nutritional and Metabolic Diseases (10) · Pathologic Processes (10) · Pathological Conditions, Signs and Symptoms (10) · Skin and Connective Tissue Diseases (10)
idursulfase (2) · GAA protein, human (1) · GALNS protein, human (1) · Iduronidase (1) · Sebelipase alfa (1) · Stem Cell Transplantation (1) · galsulfase (1) · vestronidase alfa (1)
ArmaGen, Inc (1) · Denali Therapeutics Inc. (1) · Green Cross Corporation (1) · Homology Medicines, Inc (1) · REGENXBIO Inc. (1) · Sangamo Therapeutics (1) · Shire (1) · Takeda (1) · Talaris Therapeutics Inc. (1) · University of California, San Francisco (1)
United States (9) · Canada (4) · United Kingdom (3) · Germany (1) · Netherlands (1) · Philippines (1) · South Korea (1)
Patrice Rioux, MD PhD (1) · Sam Lu, MD (1) · Suzanne T Ildstad, MD (1) · Tippi MacKenzie, MD (1)
PMID 15324318, PMID 19948615, PMID 21637107, PMID 23497636, PMID 23510062, PMID 28374935, PMID 28657663, PMID 30337566, PMID 32102934, PMID 35588317, PMID 36299240, PMID 37955580, PMID 39891377, PMID 41467650, PMID 9918480
2019 (1), 2023 (1)